ECLS | Extracorporeal Membrane Oxygenation

Registry Dashboard of ECMO-Supported COVID-19 Patient Data

Thank you for helping ELSO disseminate information by entering your experience in the ELSO Registry as soon as ECMO is implanted - before the run is complete. Instructions for entering data in the Registry and COVID-19 addendum can be found on the Data Definitions page.

We recognize you cannot complete and submit the entire ELSO Registry case report form prior to completion of the ECMO run and discharge from the hospital, but we would still like to have the data you know now.

To address concerns about incomplete data we report three nested data sets to accommodate the fact that different patients will be at different stages of care (and thus have more or less incomplete data). Also when considering the data please understand that the data displayed is a real-time data stream and subject to change as more patient information is accrued and as centers update the ELSO Registry Case Report Form and the ELSO COVID-19 addendum.



COVID-19 Cases on ECMO in the ELSO Registry

Total COVID-19 Cases COVID-19
Confirmed Cases
17,438
Total counts of COVID-19 confirmed patients.

COVID-19 ECMO counts by ELSO Chapter

Still on ECMO Still Hospitalized at ELSO Center Total (n)
All ELSO 373 696 17,531
          North America 92 168 11,080
          Europe 141 198 3,489
          Asia Pacific 41 92 525
          Latin America 75 190 1,265
          SWAAC 24 48 1,171
Reports counts of ECMO-supported suspected or confirmed COVID-19 cases by ELSO Chapter

Filters affect the data shown in the tables below:

Year To Date

Region

Patient Age


Patients who initiated ECMO at
least 90 days ago
COVID-19
Confirmed
15,959
COVID-19
In-hospital Mortality
48%

Outcomes

Pre-ECMO Patient Factors

Patient-level summaries of COVID ECMO runs. All categorical variables are given as 'percentage (count)'
Total ARDS Cohort
Number cases 15959 11836
Age(years)
Median(IQR) 47(37,56) 48(38,56)
# observed 15959 11836
BMI, kg/m2
Median(IQR) 32(27,37) 32(28,38)
# observed 14819 10966
Sex
Male 68%(10895) 70%(8241)
Female 32%(5060) 30%(3592)
# observed 15955 11833
Race/Ethnicity
Black 11%(1682) 10%(1191)
White (Non-Hispanic) 44%(7025) 43%(5140)
Asian 9%(1361) 8%(946)
Mid East, N African 4%(694) 5%(573)
Other 3%(458) 3%(339)
Unknown 5%(781) 5%(606)
Multiple 5%(831) 6%(697)
Hispanic 20%(3127) 20%(2344)
# observed 15959 11836
Pre-ECMO Comorbidities
No comorbidity 26%(4124) 24%(2897)
Cancer 2%(289) 2%(199)
Pregnancy 4%(638) 4%(485)
Immunocompromised 5%(777) 5%(578)
Diabetes 23%(3722) 24%(2863)
Pre-existing heart disease 4%(665) 3%(330)
Pre-existing lung disease 4%(619) 4%(460)
Pre-existing renal insuff. 3%(489) 3%(337)
Frailty 1%(137) 1%(76)
Asthma 10%(1609) 10%(1225)
BMI $> 30 \mathrm{kg}/\mathrm{m}^2$ 49%(7789) 51%(6080)
Hypertension 31%(4907) 32%(3780)
# observed 15959 11836
Acute illness
ARDS 79%(12530) 100%(11836)
Acute heart failure 9%(1364) 5%(597)
Myocarditis 2%(382) 1%(65)
Acute kidney injury 26%(4183) 27%(3173)
# observed 15959 11836
Pre-ECMO Cardiac Arrest
Yes 7%(1047) 3%(356)
No 93%(14760) 97%(11361)
# observed 15807 11717
Pre-ECMO Co-Infection
No Co-infection 49%(7806) 46%(5458)
Bacterial pneumonia 44%(7019) 47%(5621)
Co-viral infection 9%(1491) 9%(1057)
Blood stream infection 18%(2863) 19%(2260)
Urinary tract infection 8%(1199) 8%(997)
# observed 15957 11834

Pre-ECMO Interventions

Support and therapies. All categorical variables are given as 'percentage (count)'
PreECLS PreECLS
Number cases 15959 11836
Noninvasive ventilation
Noninvasive ventilation prior to intubation 76%(12078) 80%(9451)
BiPAP 38%(5985) 41%(4825)
CPAP 13%(1995) 12%(1412)
HFNC 51%(8132) 55%(6514)
# observed 15959 11836
Pre-ECLS intubation (days)
Median(IQR) 2.8(0.8,5.9) 3.2(1.0,6.2)
# observed 13242 9888
Ventilator mode
Conventional 96%(12923) 97%(9918)
# observed 13498 10233
PEEP, cm H2O
Median(IQR) 14.0(10.0,16.0) 14.0(10.0,16.0)
# observed 11988 9240
PIP, cm H2O
Median(IQR) 33.0(29.0,38.0) 34.0(30.0,38.0)
# observed 9618 7355
FiO2
Median(IQR) 1.00(0.95,1.00) 1.00(1.00,1.00)
# observed 11881 9020
PaO2/FiO2
Median(IQR) 70(57,91) 70(57,89)
# observed 11611 8824
PCO2
Median(IQR) 60(49,74) 61(51,75)
# observed 12354 9339
Pre-ECMO Support
Prone positioning 51%(8127) 56%(6565)
# observed 15880 11782
Neuromuscular blockers 67%(10638) 72%(8427)
# observed 15883 11781
Inhaled pulmonary vasodilators 28%(4395) 30%(3573)
# observed 15880 11782
Any vasoactive support 57%(9101) 56%(6579)
# observed 15879 11777
Norepinephrine 51%(8058) 51%(5986)
# observed 15879 11777
Therapies, Immunomodulators
Any therapy 87%(13828) 90%(10646)
Glucocorticoids 78%(12417) 81%(9612)
IVIG 3%(441) 2%(236)
Anti-cytokine 21%(3412) 24%(2808)
Lopinavir/Ritonavir 2%(278) 2%(227)
JAK inhibition 4%(564) 4%(478)
Chloroquine/hydroxychloroquine 6%(1023) 7%(831)
Remdesivir 48%(7640) 51%(6063)
# observed 15959 11836
Support type
Respiratory 92%(14754) 100%(11810)
Cardiac 6%(919) 0%(12)
ECPR 2%(286) 0%(14)
# observed 15959 11836

Patient Status & Complications

Outcomes
Total ARDS Cohort
Last known patient status
Discharged alive to home or acute rehabilitation 26%(4222) 26%(3038)
Discharged alive to long-term acute care or unspecified location 12%(1853) 13%(1496)
Discharged to another hospital 12%(1865) 11%(1302)
Remain in the hospital (discharged from ICU) 0%(8) 0%(5)
Remain in the ICU 0%(48) 0%(36)
In-hospital death 50%(7963) 50%(5959)
Tracheostomy 46%(6671) 50%(5434)
# observed 14498 10761
Select complications
Seizures 1%(121) 1%(86)
# observed 15896 11783
CNS infarction by US/CT/MRI 2%(268) 1%(160)
# observed 15896 11783
CNS hemorrhage by US/CT/MRI 6%(1002) 7%(788)
# observed 15896 11783
Hemolysis 7%(1158) 8%(892)
# observed 15896 11783
Oxygenator failure 21%(3293) 23%(2729)
# observed 15896 11783
Pump failure 2%(328) 2%(260)
# observed 15896 11783
Circuit change 11%(1734) 12%(1388)
# observed 15896 11783
Thrombosis/Clots in circuit component 3%(530) 4%(425)
# observed 15896 11783
Discharge location
Home 31%(2484) 31%(1784)
Transfer to LTAC or Rehab
Transfer to another hospital 23%(1865) 22%(1302)
Other/Unknown 6%(453) 5%(317)
*N/A - Data elements with n<5 are not displayed.

ELSO Ownership, No Rights to Publication, Disclaimer

The Dashboard content has been compiled and reported from a variety of sources, is not independently verified by ELSO, and is subject to change without notice. ELSO and its authorized agents and contractors make no representations or warranties about the quality, content, completeness, suitability, adequacy, sequence, accuracy, or timeliness of such content. ELSO disclaims any responsibility for any inaccuracy, whether by inclusion or omission, on the Dashboard or the Site, and disclaims any responsibility for subsequent change or withdrawal of data shown on the Dashboard or the Site, which is subject to alteration without notice. ELSO disclaims any and all warranties regarding this information and all liability whatsoever relating thereto. Any person who uses information obtained from this Dashboard does so at his or her own risk.

The Dashboard is provided as a public service to facilitate real-time sharing of information during the COVID-19 crisis for educational purposes only by health practitioners. ELSO owns the compilation of all data, and its use or publication by any third party is strictly forbidden. Publication or representation of this information as if it were statistically significant or part of a scientific study is irresponsible and misleading.

The tables are consistent with the Lancet Publication article but the data presented here is real time

Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, Bartlett RH, Tonna JE, Hyslop R, Fanning JJ, Rycus PT, Hyer SJ, Anders MM, Agerstrand CL, Hryniewicz K, Diaz R, Lorusso R, Combes A, Brodie D, the Extracorporeal Life Support Organization. Extracorporeal Membrane Oxygenation Support in COVID-19: The Registry Report from the Extracorporeal Life Support Organization. Lancet. 2020; [In Press].

We’ve updated our Privacy Policy. By continuing to use this Service, you acknowledge you’ve read the updated Privacy Policy.